Patients treated with PCI in the years from 2010 to 2014 in the US Nationwide Readmission Database were evaluated for the influence of
cancer on 90-day readmissions for AMI and
bleeding. A total of 1 933 324 patients were included in the analysis (2.7% active
cancer, 6.8% previous history of
cancer). The 90-day readmission for AMI after PCI was higher in patients with active
cancer (12.1% in lung, 10.8% in colon, 7.5% in breast, 7.0% in prostate, and 9.1% for all
cancers) compared to 5.6% among patients with no
cancer. The 90-day readmission for
bleeding after PCI was higher in patients with active
cancer (4.2% in colon, 1.5% in lung, 1.4% in prostate, 0.6% in breast, and 1.6% in all
cancer) compared to 0.6% among patients with no
cancer. The average time to AMI readmission ranged from 26.7 days for
lung cancer to 30.5 days in
colon cancer, while the average time to
bleeding readmission had a higher range from 38.2 days in
colon cancer to 42.7 days in
breast cancer.
CONCLUSIONS: Following PCI, patients with
cancer have increased risk for readmissions for AMI or
bleeding, with the magnitude of risk depending on both
cancer type and the presence of
metastasis.